HRT and Surgery: What to Stop, When to Restart, and Everything In Between

Why Surgery Changes the HRT Equation

Estrogen raises coagulation factor levels and reduces the natural anticoagulant protein S, shifting the blood toward a pro-thrombotic state. Surgery amplifies that same shift through immobility, tissue trauma, and a systemic inflammatory response. The combination can raise VTE risk substantially above either factor alone.

A 2006 cohort analysis published in the BMJ found that women taking combined oral HRT had approximately twice the odds of postoperative deep vein thrombosis (DVT) or pulmonary embolism (PE) compared with non-users undergoing the same procedures [1]. That signal is consistent enough that every major perioperative guideline now addresses HRT explicitly.

The key variable is route of administration. Oral estrogen undergoes first-pass liver metabolism, which drives up prothrombotic factors far more than the same estrogen delivered through skin. A large observational study in the BMJ (Canonico et al., 2007, N=881 postmenopausal women with first VTE) found transdermal estradiol was not associated with elevated VTE risk, while oral estrogen carried an odds ratio of approximately 4.2 for VTE [2]. This pharmacokinetic difference is the reason clinical guidance treats oral and transdermal HRT as two separate risk categories in the surgical setting.

Exactly When to Stop HRT Before Surgery

For oral combined HRT or oral estrogen-only preparations, the standard recommendation is to stop four weeks before any major elective procedure, particularly those involving general anaesthesia, pelvic surgery, prolonged immobility, or orthopaedic lower-limb work. The Royal College of Obstetricians and Gynaecologists (RCOG) and the British Menopause Society both endorse this four-week window, which is designed to allow hepatic coagulation factor levels to normalize [3].

Four weeks is not arbitrary. Prothrombin fragment 1.2 and D-dimer levels, reliable markers of coagulation activation, return toward baseline within three to four weeks of stopping oral estradiol in most women. Stopping two weeks out is not long enough for high-risk procedures.

Transdermal preparations, including patches, gels, and sprays, carry a substantially lower perioperative risk. Current guidance from the British Menopause Society states that transdermal estrogen does not need to be routinely stopped before surgery, though the final decision should incorporate the individual's personal VTE history, thrombophilia screen results, and procedure type [4]. Women with a prior DVT or a known thrombophilia such as Factor V Leiden should discuss prophylactic low-molecular-weight heparin (LMWH) with their surgeon regardless of route.

Progesterone adds another layer. Oral medroxyprogesterone acetate (MPA), used in older combined preparations like Premarin/Provera, contributes independently to VTE risk. Micronized progesterone (Utrogestan) and the levonorgestrel intrauterine system appear to add little to no additional clot risk, based on the E3N cohort data involving over 80,000 French women followed for a mean of 8.1 years [5].

Practical stopping checklist for a scheduled procedure:

1. Identify whether your estrogen is oral or transdermal.
2. Identify whether your progestogen is synthetic (MPA, norethisterone) or body-identical (micronized progesterone, LNG-IUS).
3. If oral estrogen or synthetic progestogen: stop four weeks before surgery, inform the surgical and anaesthetic team, and document it clearly.
4. If transdermal estrogen with body-identical progesterone: discuss with your prescriber but stopping is often unnecessary.
5. Ask about LMWH prophylaxis if you have added risk factors.

When to Restart HRT After Surgery

Restarting HRT after surgery is not simply the mirror image of stopping it. The postoperative period introduces its own thrombotic risks: immobility, wound-related inflammation, dehydration, and reduced ambulation can persist for days to weeks.

A reasonable clinical approach is to wait until the patient is fully mobile, eating and drinking normally, and at low estimated VTE risk before restarting any estrogen. For most day-case or short-stay procedures that entails two to four days. For major abdominal, pelvic, or orthopaedic surgery, that window extends to two to four weeks or until the surgeon confirms adequate mobilization.

Transdermal formulations are the preferred choice at restart precisely because they can be initiated while some VTE risk is still present without the hepatic coagulation burden of oral preparations. If a woman was previously on an oral formulation, the perioperative period is a logical time to discuss switching to a patch or gel as a longer-term strategy.

The HealthRX Perioperative HRT Framework below summarizes the decision in clinical shorthand:

| Formulation | Stop before elective major surgery? | Restart timing | |---|---|---| | Oral estrogen (any dose) | Yes, 4 weeks prior | 2 to 4 weeks post-op, when mobile | | Transdermal estrogen (patch/gel) | Usually no; discuss if VTE history | 2 to 4 days post-op for minor; 1 to 2 weeks for major | | Synthetic progestogen (MPA, norethisterone) | Yes, with oral estrogen | Same as above | | Micronized progesterone / LNG-IUS | Usually no | Usually no pause needed | | Vaginal estrogen (low-dose topical) | No | No pause needed |

How Fast Does HRT Work

Most women want relief from hot flashes, night sweats, and sleep disruption as quickly as possible after starting HRT. Symptom timelines vary by formulation and symptom type.

Vasomotor symptoms, including hot flashes and night sweats, typically begin to improve within two to four weeks of starting a therapeutic estrogen dose. A 2021 Cochrane review of estrogen therapy for menopausal symptoms (52 trials, over 28,000 participants) confirmed that women on estradiol reported meaningful reductions in hot flash frequency and severity compared with placebo from week four onward, with maximum benefit generally reached at 8 to 12 weeks [6]. Sleep quality follows a similar trajectory, often improving in parallel with reduced night sweats.

Vaginal and urogenital symptoms, including dryness, dyspareunia, and recurrent urinary tract infections, respond more slowly. Structural changes to vaginal epithelium, the return of glycogen-rich superficial cells, take six to twelve weeks to consolidate. Some women report partial relief earlier, particularly with local vaginal estrogen applied directly to tissue.

Bone density is the slowest outcome. Dual-energy X-ray absorptiometry (DEXA) studies show that estrogen therapy increases lumbar spine bone mineral density by approximately 1 to 2 percent per year during the first three years of use [7]. Clinically meaningful fracture risk reduction requires sustained therapy over years, not weeks.

Mood and cognitive effects are inconsistent across studies and appear to be most pronounced in women who initiate HRT early in the menopausal transition, within six years of final menstrual period, an observation aligned with the "window of opportunity" hypothesis discussed in the WHIMS sub-study data [8].

Can You Stop HRT Cold Turkey

Stopping HRT abruptly is physically safe in most cases, but it is not comfortable. The ovarian estrogen it was replacing is gone; the replacement stops; menopausal symptoms return. How quickly and how severely depends on individual sensitivity, duration of use, and the dose being stopped.

Women who stop abruptly after months or years of therapy typically experience a return of hot flashes, night sweats, and sleep disruption within days to two weeks. A minority report a brief worsening above their pre-treatment baseline, sometimes described as a rebound effect, though the evidence for a true pharmacologic rebound is limited.

Gradual dose reduction is preferred over abrupt discontinuation wherever there is clinical flexibility. The British Menopause Society recommends stepping down the estrogen dose over several months rather than stopping outright, giving the hypothalamic thermoregulatory center time to re-adapt [4]. For example, a woman on 100 mcg estradiol patches might step down to 75 mcg for six weeks, then 50 mcg for six weeks, then 25 mcg for six weeks before stopping.

Cold turkey is sometimes unavoidable, particularly in the surgical context discussed above or when a serious side effect emerges. In those scenarios, non-hormonal options, including venlafaxine 37.5 to 75 mg daily, gabapentin 300 mg three times daily, or oxybutynin for urge-predominant urinary symptoms, can blunt the symptom rebound. The North American Menopause Society (NAMS) 2023 Position Statement identifies low-dose venlafaxine and paroxetine 7.5 mg (Brisdelle) as the best-supported non-hormonal options for vasomotor symptoms [9].

One category requires particular care: women who started HRT for premature ovarian insufficiency (POI), defined as menopause before age 40. These women carry a 30 to 40 percent higher lifetime fracture risk than women with typical menopause timing. Abrupt discontinuation in POI, without a concrete plan for alternative bone protection, should trigger urgent specialist review.

How Long Can You Stay on HRT

There is no biologically mandated upper time limit for HRT use. The oft-quoted five-year rule originated from early interpretations of the Women's Health Initiative (WHI), a 2002 study of conjugated equine estrogen plus MPA in mostly older women (mean age 63 at enrollment) with a baseline cardiovascular risk profile unrepresentative of newly menopausal women in their early 50s [10].

Subsequent re-analyses and observational cohort data have substantially revised the risk-benefit picture for women who start HRT within 10 years of menopause or before age 60. The 2022 NICE guideline NG23 (updated) states that there is no arbitrary limit on duration, and that the decision should be based on ongoing shared risk-benefit discussion taking into account symptom burden, bone and cardiovascular health, personal cancer history, and patient preference [11].

Breast cancer is the risk most often cited. The Collaborative Group on Hormonal Factors in Breast Cancer (2019, Lancet, N=108,647 breast cancer cases) found that combined estrogen-progestogen HRT was associated with an excess of approximately 6 additional breast cancers per 1,000 users over five years of use, rising to approximately 19 per 1,000 over 10 years [12]. Estrogen-only HRT in hysterectomized women showed a smaller and in some analyses absent increase in breast cancer risk, particularly with transdermal estradiol and micronized progesterone.

Annual review is the standard of care. At each review the prescriber should reassess symptom burden, any new personal or family history, current formulation, dose, and the woman's informed preference. Many women choose to continue beyond five or ten years, particularly for bone protection, cardiovascular considerations in early surgical menopause, and quality of life. That choice, made with full information, is supported by current evidence.

HRT and Pregnancy

HRT is not a contraceptive. This point is consistently underestimated, and the consequences of assuming otherwise are significant.

Perimenopause, the years leading up to the final menstrual period, can last four to eight years. During this time, ovulation remains possible even with irregular cycles. A 2018 FSRH guideline on contraception in perimenopause states that women under age 50 should use effective contraception for two years after their last menstrual period, and women over age 50 for one year [13].

Estradiol doses used in standard HRT (typically 1 to 2 mg oral or 50 to 100 mcg transdermal) do not suppress ovulation reliably. The levonorgestrel intrauterine system (LNG-IUS, Mirena) serves a dual function here: it provides endometrial protection when combined with systemic estrogen and simultaneously acts as a highly effective contraceptive. That combination is one reason the LNG-IUS is frequently the recommended choice for perimenopausal women on HRT who have not yet confirmed menopause.

Confirmed menopause is defined as 12 consecutive months of amenorrhoea in the absence of other causes. FSH above 30 IU/L on two tests at least six weeks apart, both drawn without exogenous estrogen influence, also supports the diagnosis, though FSH can fluctuate unpredictably during perimenopause. Women on HRT cannot use FSH to confirm menopause accurately because exogenous estrogen suppresses pituitary FSH output.

If a perimenopausal woman on HRT does conceive, the estrogen and progestogen doses in HRT formulations are substantially lower than in oral contraceptive pills and are unlikely to cause fetal harm in early pregnancy, but HRT should be stopped immediately and obstetric review arranged. Progesterone supplementation in the first trimester for luteal phase support is an entirely different clinical scenario from HRT and should not be confused with it.

Special Populations: Premature Ovarian Insufficiency and Surgical Menopause

Women with POI or surgical menopause (bilateral oophorectomy before natural menopause) face a different risk profile than women with typical menopause at age 51 to 52. These women lose estrogen decades ahead of the expected timeline, accruing cardiovascular and skeletal risks earlier than the general population.

The NICE guideline for POI (NG23) recommends HRT or combined oral contraceptive use in POI until at least the average age of menopause, approximately 51, to protect bone and cardiovascular health [11]. The ESHRE POI guideline (2024) concurs, recommending estrogen replacement at physiological doses (equivalent to 100 mcg transdermal estradiol or higher) rather than the lower maintenance doses often used for symptom control in typical menopause [14].

Surgical menopause due to bilateral oophorectomy produces an immediate and complete loss of ovarian estrogen, often causing more severe acute symptoms than natural menopause. Starting HRT within days of surgery, once the surgeon confirms no contraindication, reduces the acute vasomotor burden and limits early bone loss. Women who have had oophorectomy and hysterectomy can use estrogen-only HRT, avoiding the added progestogen exposure entirely.

Monitoring and Dose Adjustment

Starting HRT is not a set-and-forget prescription. The first review should occur at three months, assessing symptom control, side effects, and any unexpected bleeding patterns. The MHT (menopausal hormone therapy) dose should then be titrated to the lowest amount that achieves acceptable symptom control.

Unscheduled or unexpected vaginal bleeding on HRT requires endometrial evaluation, typically transvaginal ultrasound and endometrial biopsy, to exclude endometrial hyperplasia or carcinoma. An endometrial thickness above 4 mm on ultrasound in a postmenopausal woman on sequential HRT warrants further investigation [15].

Blood pressure does not typically worsen with transdermal estrogen; oral estrogen may raise systolic blood pressure modestly in some women through renin-angiotensin activation. Liver function is relevant if switching to oral preparations in women with known hepatic disease. No routine blood estrogen level monitoring is required for symptom-based dosing in otherwise healthy women, though levels can be useful in POI to confirm adequate replacement.

Women on anticoagulants such as warfarin should be aware that initiation or cessation of oral estrogen may alter INR; additional INR checks at two to four weeks after any change in HRT are reasonable.

For women preparing for surgery, the bottom line is this: stop oral estrogen-containing HRT four weeks before the procedure, confirm your surgeon and anaesthetist know your full hormonal history, and plan your restart date before you go under.